1.
Megna M, Potestio L, Battista T, et al. Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics. Clin Exp Dermatol. 2022; 47(12):2310-2312.
2.
Frühauf J, Schwantzer G, Ambros-Rudolph CM, et al. Pilot study on the acceptance of mobile teledermatology for the home monitoring of high-need patients with psoriasis. Australas J Dermatol. 2012;53(1):41-46.
3.
Julie ZY, Reynolds RV, Olbricht SM, McGee JS. Moving forward with teledermatology: Operational challenges of a hybrid in-person and virtual practice. Clin Dermatol. 2021;39(4):707-709.
4.
Ferwerda M, Van Beugen S, Van Burik A, et al. What patients think about E-health: patients’ perspective on internet-based cognitive behavioral treatment for patients with rheumatoid arthritis and psoriasis. Clin Rheumatol. 2013;32(6):869-873.
5.
Schmid-Grendelmeier P, Takaoka R, Ahogo K, et al. Position statement on atopic dermatitis in sub-Saharan Africa: current status and roadmap. J Eur Acad Dermatol Venereol. 2019; 33(11):2019-2028.
6.
Izquierdo-Domínguez A, Rojas-Lechuga MJ, Alobid I. Management of allergic diseases during COVID-19 outbreak. Curr Allergy Asthma Rep. 2021;21(2):8.
7.
Armstrong AW, Chambers CJ, Maverakis E, et al. Effectiveness of online vs. in-person care for adults with psoriasis: a randomized clinical trial. JAMA Netw Open. 2018;1(6):e183062.
8.
Martora F, Picone V, Fabbrocini G, Marasca C. Hidradenitis suppurativa flares following COVID-19 vaccination: a case series. JAAD Case Rep. 2022;23:42-45.
9.
Alexander H, Patel NP. Response to Martora et al.’s “Hidradenitis suppurativa flares following COVID-19 vaccination: a case series”. JAAD Case Rep. 2022;25:13-14.
10.
Ruggiero A, Martora F, Picone V, Marano L, Fabbrocini G, Marasca C. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review. Biomedicines. 2022;10(2):455.
11.
Salvador-Rodriguez L, Montero-Vílchez T, Arias-Santiago S, Molina-Leyva A. Paradoxical hidradenitis suppurativa in patients receiving TNF-α inhibitors: case series, systematic review, and case meta-analysis. Dermatol. 2020;236(4):307-313.
12.
Martora MMF, Megna M, Battista T, Potestio L. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023;16:135-148.
13.
Ford AR, Gibbons CM, Torres J, et al. Access to dermatological care with an innovative online model for psoriasis management: results from a randomized controlled trial. Telemed J E Health. 2019;25(7):619-627.
14.
Haque W, Chandy R, Ahmadzada M, Rao B. Teledermatology after COVID-19: key challenges ahead. Dermatol Online J. 2021; 27(4):13030/qt5xr0n44p.
15.
Choi E, Mak WK, Law JY, Santos D, Quek SC. Optimizing teledermatology: looking beyond the COVID-19 pandemic. Int J Dermatol. 2021;60(1):119-121.
16.
Picone V, Martora F, Fabbrocini G, Marano L. “Covid arm”: abnormal side effect after Moderna COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15197.
17.
McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55.
18.
Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292-1293.
19.
Shin SH, Hong JK, Hong SA, Li K, Yoo KH. Pityriasis rosea shortly after mRNA-1273 COVID-19 vaccination. Int J Infect Dis. 2022;114:88-89.
20.
Veraldi S, Spigariolo CB. Pityriasis rosea and COVID-19. J Med Virol. 2021;93(7):4068.
21.
Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. Dermatol Ther. 2022;35(2):e15225.
22.
Martora F, Villani A, Marasca C, Fabbrocini G, Potestio L. Skin reaction after SARS-CoV-2 vaccines reply to ‘cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience’. J Eur Acad Dermatol Venereol. 2023; 37(1):e43-e44.
23.
Avallone G, Cavallo F, Astrua C, et al. Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience. J Eur Acad Dermatol Venereol. 2022; 36(11):e876-e879.
24.
Martora F, Fabbrocini G, Nappa P, Megna M. Impact of the COVID-19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. Int J Dermatol. 2022;61(7):e237-e238.
25.
Martora F, Fabbrocini G, Nappa P, Megna M. Reply to ‘Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2’ by Solimani et al. J Eur Acad Dermatol Venereol. 2022;36(10):e750-e751.
26.
Solimani F, Mansour Y, Didona D, Dilling A, Ghoreschi K, Meier K. Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2. J Eur Acad Dermatol Venereol. 2021;35(10):e649-e651.
27.
Falcinelli F, Lamberti A, Cota C, Rubegni P, Cinotti E. Reply to ‘Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2’ by Solimani F et al. J Eur Acad Dermatol Venereol. 2022;36(12):e976-e978.
28.
Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2023;22(1):32-33.
29.
Washrawirul C, Triwatcharikorn J, Phannajit J, Ullman M, Susantitaphong P, Rerknimitr P. Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2022;36(11):1947-1968.
30.
Qaderi K, Golezar MH, Mardani A, et al. Cutaneous adverse reactions of COVID-19 vaccines: a systematic review. Dermatol Ther. 2022;35(5):e15391.
31.
Kazi R, Evankovich MR, Liu R, et al. Utilization of asynchronous and synchronous teledermatology in a large health care system during the COVID-19 pandemic.Telemedicine and e-Health. 2021;27(7): 771-777.
32.
Ruggiero A, Martora F, Fornaro F, Scalvenzi M, Fabbrocini G, Villani A. Reply to ‘Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity’ by R. Molinier, et al. J Eur Acad Dermatol Venereol. 2023; 37(2):e130-e131.
33.
Molinier R, Roger A, Genet B, et al. Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity. J Eur Acad Dermatol Venereol. 2022;36(3):e164-e166.
34.
Pasquali P, Sonthalia S, Moreno-Ramirez D, et al. Teledermatology and its current perspective. Indian Dermatol Online J. 2020;11(1):12-20.
35.
Ruggiero A, Martora F, Fabbrocini G, et al. The role of teledermatology during the COVID-19 pandemic: a narrative review. Clin Cosmet Investig Dermatol. 2022;15:2785-2793.
36.
Ruggiero A, Megna M, Fabbrocini G, Martora F. Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clin Exp Dermatol. 2022;47(10):1863-1864.
37.
Stadler PC, Senner S, Frey S, et al. Teledermatology in times of COVID-19. J Dermatol. 2021;48(5):620-624.
38.
Martora F, Marasca C, Battista T, Fabbrocini G, Ruggiero A. Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: ‘Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa’. Clin Exp Dermatol. 2022;47(11):2026-2028.
39.
Ruggiero A, Martora F, Fornaro L, et al. The impact of COVID-19 pandemic on nonmelanoma skin cancers: report of a Southern Italy referral centre. Clin Exp Dermatol. 2022;47(11):2024-2025.